Effects of Different Cardiorespiratory Training Program on Endurance Performance
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Changes in 2.4 km completion time following first cycle in phase 1
Study Overview
Brief Summary
Conventional training methods are typically administered in a fixed progressive manner, which can lead to sub-optimal responses and injuries. Artificial intelligence (i.e. CURATE.AI) can be harnessed to personalise physical training strategies. Using a single participant training profile, a parabolic/quadratic response to the intervention can be generated to identify the training intensity needed to optimise training outcomes. Previous studies showed CURATE.AI could dynamically modulate drug dosing in oncology. Extending the utility of results to human performance, this study will adapt CURATE.AI with the goal of optimising endurance performance through individualised training regimes.
Up to 20 participants will be recruited and randomised into two groups to undergo a calibration phase, which involves performing 3 sessions of exercise sessions per week over 2 weeks per intensity (low, moderate and high) in a crossover study design. Exercise sessions will be interspersed with a 2.4 km time trial, a VO2peak test and 2 weeks of wash out period. The utility phase will divide participants into two groups to undergo 3 exercise sessions per week, totalling to 12 exercise sessions. Either an AI-led training or a conventional training programme will be performed to compare the differences in training outcomes. Blood plasma will be obtained at selected time points in both phases to evaluate the effects of training on blood lipid profiles.
Findings from this study can potentially optimise efficacy and efficiency of endurance performance through personalised training with AI.
Detailed Description
Participants:
Up to 20 recreationally active healthy males, aged between 21 to 35 years, will be recruited to take part in this study. All volunteers will provide their informed consent in writing before participating in the study. The possible risk and benefits will be made known to the participant prior to the agreement to participate and they will be allowed to withdraw from the study at any point in time without any reason provided. All potential participants will first be required to undergo medical screening by a certified independent practitioner before participating in the study. The medical practitioner conducting the assessment will be informed of the purpose of the medical screening. The screening is to ensure that the potential participant is eligible to take part in the study. The personal particulars form will also be completed by each participant prior to the commencement of each trial.
Baseline measurements and familiarisation trials:
In the first session, anthropometry measurements will be taken. Based on the height and nude body mass, the body mass index (BMI) will be calculated (body mass in kg) / (height in m)2. Waist and hip circumference will be determined using a measuring tape. Skinfold thickness measurements will be taken at 4 sites (biceps, triceps, subscapular and suprailiac) in triplicate using skinfold calliper and the mean value will be used to calculate total skin fold. Body density will be calculated according to the estimation of Durnin and Womersley (1974) and percentage body fat will be estimated using the equation of Siri (1956).
Familiarisation of the 2.4 km time trial and the treadmill peak oxygen uptake (VO2peak) test will be performed 2 weeks before the commencement of the actual 2.4 km time trial. Ample rest is given between the two sessions for recovery.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Other
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 21 Years to 35 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Do not smoke or use tobacco products (including shisha)
- •BMI < 30
- •Medically fit
- •2.4 km run time of 10 to 14 minutes in the past 12 months
Exclusion Criteria
- •Individuals with a history of existing musculoskeletal injury or respiratory diseases
Outcomes
Primary Outcomes
Changes in 2.4 km completion time following first cycle in phase 1
Time Frame: Baseline and Week 4 of phase 1 (phase 1 first cycle consist of 42 days)
Time taken to complete 2.4 km
Changes in 2.4 km completion time following third cycle in phase 1
Time Frame: Baseline and Week 14 of phase 1 (phase 1 third cycle consist of 21 days)
Time taken to complete 2.4 km
Changes in 2.4 km completion time following second cycle in phase 1
Time Frame: Baseline and Week 9 of phase 1 (phase 1 second cycle consist of 35 days)
Time taken to complete 2.4 km
Changes in 2.4 km completion time following phase 2
Time Frame: Baseline and Week 6 of phase 2 (phase 2 consist of 49 days)
Time taken to complete 2.4 km
Secondary Outcomes
- Changes in VO2peak following second cycle in phase 1(Baseline and Week 9 of phase 1 (phase 1 second cycle consist of 35 days))
- Changes in blood lipids panel (triglycerides, cholesterols, phospholipids, sphingolipids, inflammatory lipids, testosterone, cortisol, endocannabinoids) pre- and post- training following second cycle in phase 1(Week 7 and 8 of phase 1 (phase 1 second cycle consist of 35 days))
- Changes in VO2peak following first cycle in phase 1(Baseline and Week 4 of phase 1 (phase 1 first cycle consist of 42 days))
- Changes in VO2peak following phase 2(Baseline and Week 6 of phase 2 (phase 2 consist of 49 days))
- Changes in blood lipids panel (triglycerides, cholesterols, phospholipids, sphingolipids, inflammatory lipids, testosterone, cortisol, endocannabinoids) pre- and post- training following third cycle in phase 1(Week 12 and 13 of phase 1 (phase 1 third cycle consist of 21 days))
- Changes in resting blood lipids panel (triglycerides, cholesterols, phospholipids, sphingolipids, inflammatory lipids, testosterone, cortisol, endocannabinoids) in phase 2(Week 1 and 7 of phase 2 (phase 2 consist of 49 days))
- Changes in VO2peak following third cycle in phase 1(Baseline and Week 14 of phase 1 (phase 1 third cycle consist of 21 days))
- Resting blood lipids panel (triglycerides, cholesterols, phospholipids, sphingolipids, inflammatory lipids, testosterone, cortisol, endocannabinoids) in phase 1(Week 1 of phase 1 (phase 1 consist of 98 days))
- Changes in blood lipids panel (triglycerides, cholesterols, phospholipids, sphingolipids, inflammatory lipids, testosterone, cortisol, endocannabinoids) pre- and post- training in phase 2(Week 2, 4 and 5 of phase 2 (phase 2 consist of 49 days))
- Changes in blood lipids panel (triglycerides, cholesterols, phospholipids, sphingolipids, inflammatory lipids, testosterone, cortisol, endocannabinoids) pre- and post- training following first cycle in phase 1(Week 2 and 3 of phase 1 (phase 1 first cycle consist of 42 days))
Investigators
Wang Yongtai Raymond
Research Associate
National University of Singapore